Related Experiment Videos
Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity
Roberto P Falcão1, Aglair B Garcia, Maria G Marques
1Department of Clinical Medicine, School of Medicine Ribeirão Preto-USP, Ribeirão Preto, SP, Brazil. rpfalcao@fmrp.usp.br
Leukemia Research
|July 20, 2002
Summary
This study details three new cases of a rare natural killer (NK) cell malignancy. The CD3-CD4+CD56+ NK blastic cells infiltrate skin, lymph nodes, and bone marrow.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- A rare natural killer (NK) cell malignancy presents with unique clinicopathologic features.
- This malignancy involves infiltration of cutaneous, nodal, and bone marrow sites.
Purpose of the Study:
- To describe the clinicopathologic and immunophenotypic characteristics of three new cases of this distinct NK cell malignancy.
- To differentiate this entity from other hematologic malignancies.
Main Methods:
- Analysis of clinical data, bone marrow smears, and peripheral blood smears.
- Immunophenotyping using flow cytometry.
- Testing for Epstein-Barr virus (EBV) DNA and T-cell receptor (TCR) gene configuration.
Main Results:
- All three cases showed infiltration by CD3-CD4+CD56+ NK blastic cells in bone marrow and peripheral blood.
- Immunophenotyping revealed identical profiles: mCD3-cytCD3-CD4+weakCD56+ HLA-DR+.
- Epstein-Barr virus (EBV) DNA was negative in tested cases, and TCR was in germline configuration.
- Negative reactions for alpha-naphthyl-acetate-esterase (ANAE), CD11b, and CD14 excluded monocytic lineage.
Conclusions:
- These findings define a distinct clinicopathologic entity of CD3-CD4+CD56+ NK cell malignancy.
- The immunophenotype and genetic findings support a blastic NK cell origin.
- This malignancy requires specific diagnostic and potentially therapeutic considerations.